GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: compound 195 [WO2021113557A1] | NX-5948 | NX5948
                                 
                                                         
                            
                            
                            
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: NX-5948 (Nurix Therapeutics) is an oral BTK protein degrader. It was designed as an alternative to BTK inhibitors for potential to treat B cell malignancies, including those that carry BTK mutations which confer resistance to existing BTK inhibitors [1-2]. In contrast to NX-2127 which degrades both BTK and IKZF3, NX-5948 selectively degrades BTK. We believe NX-5948 is compound 195 in patent WO2021113557A1 [3]. It is a structure match for the INN bexobrutideg (WHO INN proposed list 133, July 2025).
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||